Mehmet GÜNEŞ, Aslıhan İBİLOĞLU OKAN, Mehmet Cemal KAYA, Mahmut BULUT, Abdullah ATLI, Süleyman DEMİR, Bünyamin SEVİM, Yasin BEZ, Özlem DEMİRPENÇE

Major Depresif Bozuklukta Artmış High Mobility Group Box1 (HMGB1) Düzeyi

Amaç: Nükleer transkripsiyon faktörü olarak bilinen HighMobility Group Box1 (HMGB1)in inflamasyonun geç göstergesi olduğu bildirilmiştir. HMGB1in proinflamatuargöstergeler olan Tümör Nekroz Faktör-α (TNF-α), Interlökin(IL)-1β ve IL-8 aktivasyonunda önemli bir rolü olduğudüşünülmektedir. HMGB1 bağışıklık sistem hastalıklarınınseyrinde, teşhis ve hastalık prognozunun belirlenmesinderol oynamaktadır. Majör Depresif Bozukluğun (MDB) bağışıklık sistemi baskılamasının yanı sıra inflamatuar süreçlerde değişikliğe neden olduğu anlaşılmıştır. Depresyondatanı, tedavi ve prognozu etkileyen biyolojik belirleyicileroldukça sınırlıdır. Bu nedenle depresyon patofizyolojisiniaçıklamak için yeni etiyolojik modeller gerekmektedir.Literatürde insanlarda MDBde HMGB1 düzeyini inceleyençalışma bulunmamaktadır. Biz bu çalışmada MDB tanılıhastalarda HMGB1 düzeyini değerlendirerek inflamasyo- nun depresyon etiyolojisindeki yerini açıklamayı amaçladıkYöntem: Hasta grubu MDB tanılı 30 kişiden, kontrol grubuise herhangi bir psikiyatrik rahatsızlığı olmayan sağlıklı 30kişiden oluşmaktaydı. Katılımcılara bilgilendirilmiş gönüllüolur formu imzalatıldıktan sonra sosyodemografik bilgiformu ve Hamilton Depresyon Derecelendirme Ölçeği(HDDÖ), Klinik Global İzlem Ölçeği (KGİÖ) uygulandı.HMGB1 düzeyinin ölçümü için kan alındı. Bulgular: Hasta grubunun HMGB1 düzeyinin kontrol grubuna göre istatistiksel olarak anlamlı düzeyde yüksekolduğu görüldü (p

Increased High Mobility Group Box1 (HMGB1) level in major depressive disorder

Objective: It was reported that High Mobility GroupBox 1 (HMGB1), also known as the nuclear transcriptionfactor, is a late mediator of inflammation. It was thoughtthat HMGB1 has a prominent role in the activationof Tumor Necrosis Factor-α (TNF-α), Interleukin (IL)-1βand IL-8 which are proinflammatory mediators duringinflammation. HMGB1 plays a role in progress, diagnosisand prognosis of immune system illnesses. Besidessuppressing the immune system, Major DepressiveDisorder (MDD) was indicated to cause changes ininflammatory processes. Biological determinants affectingthe diagnosis, therapy, and prognosis of depression arequite limited. Therefore, new etiological models areneeded to explain the pathophysiology of depression.There is no study in the literature investigating level ofHMGB1 in MDD of the humans. This study aims to examinethe role of inflammation in the etiology of depressionbased on the HMGB1 in patients with MDD.Methods: A total of 30 patients diagnosed with MDDwere included in the study. The control group consistedof 30 healthy subjects without any psychiatric disorders. Asocio-demographic information form, Hamilton DepressionRating Scale (HDRS) and Clinical Global Impression Scale(CGIS) were administered, and blood was taken formeasurement of HMGB1 levels. Results: Significantly higher HMGB1 values were identifiedwith the patient group when compared to the controlgroup (p

PDF

___

1. Zhang J, McCauley MJ, Maher LJ, Williams MC, Israeloff NE. Mechanism of DNA flexibility enhancement by HMGB proteins. Nucleic Acids Res. 2009;37:1107-14.
2. Kang HJ, Lee H, Choi HJ, Youn JH, Shin JS, Ahn YH, Yoo JS, Paik YK, Kim H. Non-histone nuclear factor HMGB1 is phosphorylated and secreted in colon cancers. Lab Invest. 2009;89:948-59.
3. Thomas JO, Travers AA. HMG1 and 2, and related architectural DNA binding proteins. Trends Biochem Sci. 2001;26:167-74.
4. Muller S, Scaffidi P, Degryse B, Bonaldi T, Ronfani L, Agresti A, Beltrame M, Bianchi ME. New EMBO members review: the double life of HMGB1 chromatin protein: architectural factor and extracellular signal. Embo J. 2001;20:4337-40.
5. Todorova J, Pasheva E. High mobility group B1 protein interacts with its receptor RAGE in tumor cells but not in normal tissues. Oncol Lett. 2012;3:214-8.
6. Park JS, Arcaroli J, Yum HK, Yang H, Wang H, Yang KY, Choe KH, Strassheim D, Pitts TM, Tracey KJ, Abraham E. Activation of gene expression in neutrophils by high mobility group box 1 protein. Am J Physiol Cell Physiol. 2003;284:870-9.
7. Tian J, Avalos AM, Mao SY, Chen B, Senthil K, Wu H, et al.. Toll- like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol. 2007;8:487-96.
8. Degryse B, de Virgilio M. The nuclear protein HMGB1, a new kind of chemokine. FEBS Lett. 2003;553:11-7.
9. Moriwaka Y, Luo Y, Ohmori H, Fujii K, Tatsumoto N, Sasahira T, et al. HMGB1 attenuates anti-metastatic defense of the lymph nodes in colorectal cancer. Pathobiology. 2010;77:17-23.
10. Bianchi ME. HMGB1 loves company. J Leukocyte Biol. 2009;86:573-6.
11. Tuğlu C, Kara SH. Depresyon, sitokinler ve bağışıklık sistemi. Klinik Psikofarmakoloji Bülteni. 2003;13:142-150.
12. Raison CL, Capuron L, Miller AH. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol. 2006;27:24-31.
13. Janssen DG, Caniato RN, Verster JC, Baune BT. A psychoneuroimmunological review on cytokines involved in antidepressant treatment response. Hum Psychopharmacol. 2010;25:201-15.
14. Krishnadas R, Cavanagh J. Depression: an inflammatory illness? J Neurol Neurosurg Psychiatry. 2012; 83:495-502.
15. Sankowski R, Mader S, Ferrer SIV. Systemic inflammation and the brain: novel roles of genetic, molecular, and environmental cues as drivers of neurodegeneration. Front Cell Neurosci. 2015;9:1-20.
16. Terrando N, Rei Fidalgo A, Vizcaychipi M, Cibelli M, Ma D, Monaco C, et al. The impact of IL-1 modulation on the development of lipopolysaccharide-induced cognitive dysfunction. Crit Care. 2010;14:1-9.
17. Takata K, Kitamura Y, Kakimura JI, Shibagaki K, Tsuchiya D, Taniguchi T, et al. Role of high mobility group protein-1 (HMG1) in amyloid-β homeostasis. Biochem Biophys Res Comm. 2003;301:699-703.
18. Wu Ty, Liu L, Zhang W, Zhang Y, Liu YZ, Shen XL, et al. High- mobility group box-1 was released actively and involved in LPS induced depressive-like behavior. J Psychiatr Res. 2015;64:99-106.
19. Yasuhara D, Hashiguchi T, Kawahara K, Nakahara T, Harada T, Taguchi H, et al. High mobility group box 1 and refeeding- resistance in anorexia nervosa. Mol Psychiatry. 2007;12:976-7.
20. Whitman BA, Knapp DJ, Werner DF, Crews FT, Breese GR. The cytokine mRNA increase induced by withdrawal from chronic ethanol in the sterile environment of brain is mediated by CRF and HMGB1 release. Alcohol Clin Exp Res. 2013;37:2086-97.
21. Babinská K, Bucová M, Ďurmanová V, Lakatoová S, Jánoiková D, Bako J, et al. Increased plasma levels of the high mobility group box 1 protein (HMGB1) are associated with a higher score of gastrointestinal dysfunction in individuals with autism. Physiol Res. 2014;63(Suppl.4):S613-S8.
22. Guy W. ECDEU Assessment Manual for Psychopharmacology. Revised US Dept Health, Education and Welfare publication (ADM), Rockville, Md; National Institude of Mental Health. 1976;76-338.
23. Hamilton M. A Rating scale for depression. J Neurol Neurosurg Psychiat. 1960;23:56-62.
24. Akdemir A, Örsel SD, Dağ İ, Türkçapar H, İşcan N, Özbay H. Hamilton depresyon derecelendirme ölçeğinin geçerlililği- güvenirliliği ve klinikte kullanımı. Psikiyatri Psikoloji ve Psikofarmakoloji Dergisi. 1996;4:251-9.
25. Sha Y, Zmijewski J, Xu Z, Abraham E. HMGB1 Develops Enhanced Proinflammatory Activity by Binding to Cytokines. J Immunol. 2008;180:2531-7.
26. Fonseka TM, Mclntyre RS, Soczynska JK, Kennedy SH. Novel investigational drugs targeting IL-6 signaling for the treatment of depression. Expert Opin Investig Drugs. 2015;24:459-75.
27. Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, et al. A metaanalysis of cytokines in major depression. Biol Psychiatry. 2010;67:446-57.
28. Howren MB, Lamkin DM, Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med. 2009;71:171-86.
29. Maes M, Ringel K, Kubera M, Berk M, Rybakowski J. Increased autoimmune activity against 5-HT: a key component of depression that is associated with inflammation and activation of cell- mediated immunity, and with severity and staging of depression. J Affect Disord. 2012;136:386-92.
30. Raedler TJ. Inflammatory mechanisms in major depressive disorder. Curr Opin Psychiatry. 2011;24:519-25.
31. Seidel A, Arolt V, Hunstiger M, Rink L, Behnisch A, Kirchner H. Cytokine production and serum proteins in depression. Scand J Immunol. 1995;41:534-8.
32. Zorilla EP, Luborsky L, McKay J, Rosenthal R, Houldin A, Tax A, et al. The relationship of depression and stressors to immunological assays: a metaanalytic review. Brain Behaviour Immunity. 2001;15:199-226.
33. Mc Adams C, Leonard BE. Neutrophil and monocyte phagocytosis in depressed patients. Prog Neuro-Psychopharmacol Biol Psychiatry. 1993;17:971-84.
34. Schleifer SJ, Keller SE, Bartlett JA, Eckholdt HM, Delaney BR. Immunity in young adults with major depressive disorder. Am J Psychiatry. 1996;153:477-82.
35. Ravindran AV, Griffiths J, Merali Z, Anisman H. Circulating lymphocyte subsets in major depression and dysthymia with typical or atypical features. Psychosom Med. 1998;60:283-9.
36. Mittwoch-Jaffe T, Shalit F, Srendi B, Yehuda S. Modification of cytokine secretion following mild emotional stimuli. Neuroreport. 1995;6:789-92.